EBOS Pharmaceuticals ceo Patrick Davies yesterday reaffirmed a "positive start for the first half of the financial year," with the company releasing the formal Interim Report detailing activities for the six months to 31 Dec.
Davies said earnings for the full year are expected to be at the "upper end" of a previously forecast range of 7-10% growth in net profit after tax.
Profit for the period was $68.8 million, up of 7.2% on the prior half-year results (PD 22 Feb).
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Mar 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Mar 17
